🔄 Metformin Cancer Research

Metformin is a commonly prescribed medication for type 2 diabetes that has gained significant attention in cancer research circles. Originally developed to manage blood sugar levels, researchers have begun investigating whether this affordable, well-tolerated drug might offer additional benefits in cancer prevention and treatment. The medication's mechanism of action—which includes reducing insulin levels, activating cellular energy sensors, and potentially inhibiting cancer cell growth—has sparked considerable scientific interest in recent years.

The connection between metformin and cancer emerged from epidemiological observations showing that diabetic patients taking metformin had lower cancer incidence rates compared to those on other diabetes medications. This observation prompted numerous laboratory and clinical investigations to understand whether metformin could slow cancer development or enhance the effectiveness of standard cancer treatments. While metformin is not an approved cancer medication, its potential as an off-label therapeutic option is being actively explored in multiple cancer types, including breast, colorectal, pancreatic, and lung cancers.

On this page, you'll find comprehensive information about metformin's role in cancer research, including how it may work against cancer cells, the current state of clinical and preclinical studies, and what experts say about its potential benefits and limitations. The articles and resources below represent the latest peer-reviewed research and medical insights on this promising therapeutic avenue. Whether you're a patient, caregiver, or simply seeking to understand emerging cancer treatments, this information is intended to inform your conversations with your healthcare team.